Trastuzumab 440mg Injection
Trastuzumab 440mg injection is used for the treatment of breast cancer, multiple myeloma, and ovarian cancer. The injection is used as an adjunct treatment for cancer. The medicine is also helpful in the treatment with medicines like doxorubicin, cyclophosphamide, paclitaxel, and docetaxel. The medication comes under the international brand of Herceptin and an Indian brand name of Biceltis.
Trastuzumab 440mg injection comes under the category of alkylating agents. This medication works by stopping the growth of cancer cells in the user body. this medication is useful in controlling the multiplication of cancer cells.
Drug interactions are observed with this injection is of prescription type or non-prescription type. Always take the advice of the doctor for starting and stopping any kind of other drugs with this injection. This will ensure minimum side-effects in the body. nalidixic acid can be taken with this injection.
1. What is Biceltis 440 mg Injection?
Biceltis 440 mg Injection contains trastuzumab, a monoclonal antibody used as an anticancer medicine. Lotus International lists Biceltis as an Indian brand corresponding to the international brand Herceptin.
2. What is Biceltis used for?
Biceltis (Trastuzumab) is used in the treatment of certain HER2-positive cancers, particularly certain types of breast cancer. Its use depends on the patient’s diagnosis and treatment plan prescribed by an oncologist.
3. How does Biceltis (Trastuzumab) work?
Trastuzumab targets the HER2 protein found on certain cancer cells. By binding to HER2, it can help inhibit the growth and survival of HER2-positive cancer cells.
4. How is Biceltis 440 mg Injection administered?
Biceltis is administered by intravenous infusion under the supervision of a qualified healthcare professional. The dosage and treatment schedule are determined according to the patient’s condition and medical response.
5. What are the possible side effects of Biceltis?
Possible side effects may include nausea, vomiting, diarrhea, fatigue, headache, mouth sores, shortness of breath, and other reactions. Patients should immediately inform their healthcare professional about severe or unusual symptoms.